Angiogenèse
Les inhibiteurs de l'angiogenèse sont des composés qui interfèrent avec la formation de nouveaux vaisseaux sanguins, un processus crucial dans la croissance et la métastase des cancers. En inhibant l'angiogenèse, ces composés peuvent restreindre l'apport sanguin aux tumeurs, ralentissant ou arrêtant leur croissance. Les inhibiteurs de l'angiogenèse sont essentiels dans la recherche sur le cancer et le développement thérapeutique, offrant des informations sur les mécanismes de progression tumorale et proposant des traitements potentiels pour le cancer et d'autres maladies liées à l'angiogenèse. Chez CymitQuimica, nous offrons une large gamme d'inhibiteurs de l'angiogenèse de haute qualité pour soutenir vos recherches en oncologie et biologie vasculaire.
Sous-catégories appartenant à la catégorie "Angiogenèse"
- BTK(167 produits)
- Bcr-Abl(118 produits)
- EGFR(581 produits)
- FAK(72 produits)
- FLT(86 produits)
- Récepteur du facteur de croissance des fibroblastes (FGFR)(180 produits)
- JAK(243 produits)
- PDGFR(129 produits)
- RAAS(89 produits)
- Src(82 produits)
- Syk(37 produits)
- Thrombine(57 produits)
- VDA(2 produits)
- VEGFR(242 produits)
Affichez 6 plus de sous-catégories
2382 produits trouvés pour "Angiogenèse"
Trier par
Degré de pureté (%)
0
100
|
0
|
50
|
90
|
95
|
100
Multi-kinase-IN-4
Multi-kinase-IN-4 (compound 5d) is a multi-targeted kinase inhibitor active against VEGFR2, EGFR, HER2, and CDK2, with respective IC50 values of 0.33, 0.22, 0.Formule :C21H20ClFN2OSDegré de pureté :98%Couleur et forme :SolidMasse moléculaire :402.91VSLRGDTRG acetate
VSLRGDTRG acetate is a synthetic peptide of the RGD motif from cadherin17 (CDH17), capable of binding to α2β1 integrin and activating its signaling pathways. It facilitates the high-affinity conformational change of β1 integrin via the RGD motif, enhancing cell adhesion and phosphorylation of FAK and ERK1/2, thereby promoting tumor proliferation and metastasis. VSLRGDTRG acetate is applicable in research on cancers expressing CDH17, such as colon and pancreatic cancers.Couleur et forme :Odour SolidEGFR-IN-140
EGFR-IN-140 (Compound 31) is an inhibitor of EGFR, effectively targeting both wild-type EGFR and the EGFRL858R/T790M/C797S mutant, with Ki values of 0.95 nM and 2.1 nM, respectively. Additionally, it inhibits EGFRdel19/T790M/C797S in Ba/F3 cells with an IC50 of 56.9 nM and demonstrates antitumor activity in mouse models.Formule :C27H37FN8O2Couleur et forme :SolidMasse moléculaire :524.633SJF620 hydrochloride
CAS :SJF620 hydrochloride is a PROTAC that utilizes a lenalidomide analog to recruit CRBN and ligands to target Btk, exhibiting a DC50 of 7.9 nM [1].Formule :C41H45ClN8O7Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :797.3MS9449
CAS :MS9449 is a powerful EGFR PROTAC; Kd: 17 nM (WT), 10 nM (L858R); targets mutant EGFRs via UPS and autophagy; hinders NSCLC cell growth.Formule :C60H76ClFN10O8SDegré de pureté :98%Couleur et forme :SolidMasse moléculaire :1151.82PF15
CAS :PF15, a PROTAC for FLT3-ITD, degrades FLT3 kinase. DC50: 76.7 nM; hinders FLT3-ITD+ cell growth; potential in leukemia.Formule :C44H49N13O6Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :855.94QL-X-138 HCl
QL-X-138 HCl is a BTK/MNK dual kinase inhibitor with anticancer activity and anti-dengue virus 2 activity that inhibits BTK, MNK1, and MNK2 kinases.Formule :C25H20ClN5O2Degré de pureté :99.25%Couleur et forme :SoildMasse moléculaire :457.91DSPE-PEG2000-A7R
DSPE-PEG2000-A7R is a PEG compound consisting of DSPE and a tumor vasculature-targeting peptide (A7R). A7R exhibits high affinity and specificity for VEGFR-2, a receptor that is overexpressed in various tumors.Couleur et forme :Odour SolidDSPE-PEG5000-GE11
DSPE-PEG5000-GE11 is a PEG compound composed of DSPE and the EGFR-targeting peptide (GE11). GE11 is applicable for cancer cells with EGFR overexpression. DSPE-PEG5000-GE11 is utilized in drug delivery.Couleur et forme :Odour SolidEGFR-IN-43
EGFR-IN-43 (17c) is a potent EGFR inhibitor with ER antagonist action, tamoxifen/endoxifen+gefitinib linkage, and strong anticancer activity.Formule :C50H55ClFN5O5Couleur et forme :SolidMasse moléculaire :860.45AZ12672857
CAS :AZ12672857 is an inhibitor of EphB4 with IC50 of 1.3 nM.
Formule :C26H30N8O2Degré de pureté :98.99%Couleur et forme :SolidMasse moléculaire :486.57WYE-687
CAS :WYE-687 is a selective mTOR inhibitor (IC50: 7 nM), over 100x more selective for mTOR than PI3Kα/γ, affecting mTORC1/pS6K and mTORC2/P-AKT(S473).Formule :C28H32N8O3Degré de pureté :99.93%Couleur et forme :SolidMasse moléculaire :528.61PACAP-38 (31-38), human, mouse, rat
CAS :PACAP-38 (31-38), human, mouse, rat demonstrates potent, efficacious, and sustained stimulatory effects on sympathetic neuronal NPY and catecholamine productionFormule :C47H83N17O11Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :1062.27FLT3/IRAK4-IN-1
FLT3/IRAK4-IN-1 is a selective inhibitor of FLT3 and IRAK4, exhibiting significant activity against FLT3-WT (IC50= 1.95 nM), FLT3-D835Y (IC50= 3.22 nM), and IRAK4 (IC50= 53.72 nM). It demonstrates low cytotoxicity towards normal bone marrow cells, effectively promotes apoptosis, and has potential to overcome resistance. FLT3/IRAK4-IN-1 can be utilized in studies of acute myeloid leukemia (AML).Couleur et forme :Odour SolidK882
K882 (Compound 4e) is an Src inhibitor with a KD of 0.315 μM. It induces apoptosis and inhibits XIAP and Survivin. Additionally, K882 blocks the activation of the PI3K/Akt/mTOR, Jak1/Stat3, and Ras/MAPK signaling pathways. K882 exhibits antitumor activity against non-small cell lung cancer.Formule :C18H16N2O2Couleur et forme :SolidMasse moléculaire :292.33SNIPER(ABL)-044
SNIPER(ABL)-044, a compound that links HG-7-85-01 (ABL inhibitor) to Bestatin (IAP ligand) via a linker, effectively reduces BCR-ABL protein levels, achieving aFormule :C51H64F3N9O8SDegré de pureté :98%Couleur et forme :SolidMasse moléculaire :1020.17LH168
LH168 is a potent and selective probe for WDR5, with a SPR Kd value of 13 nM.Formule :C29H31F3N6O2SCouleur et forme :SolidMasse moléculaire :584.66FLT3-IN-21
FLT3-IN-21 (compound LC-3), a potent FLT3 inhibitor with an IC50 value of 8.4 nM, induces apoptosis and arrests the cell cycle in the G1 phase.Formule :C20H22FN5O2Couleur et forme :SolidMasse moléculaire :383.42PROTAC BTK Degrader-2
CAS :PROTAC BTK Degrader-2, a potent degrader of BTK through the PROTAC mechanism, effectively diminishes BTK protein levels [1].Formule :C47H54F2N8O13Couleur et forme :SolidMasse moléculaire :976.97dALK-3
dALK-3 is a degrader of anaplastic lymphoma kinase (ALK) that effectively induces the degradation of EML4-ALK with a DC50 of 0.182 μM. It exhibits significant antiproliferative activity against H3122 cells and is applicable for tumor research.Formule :C39H45ClN7O5PCouleur et forme :SolidMasse moléculaire :758.245FAK-IN-24
CAS :FAK-IN-24 (Compound 9f) is a potent FAK inhibitor with an IC50 of 0.815 nM. It induces DNA damage and apoptosis, and exhibits activity against glioblastoma. FAK-IN-24 effectively inhibits proliferation of glioblastoma cell lines U87-MG (IC50= 15 nM) and U251 (IC50= 20 nM), and suppresses tumor growth in U87-MG xenograft models.Formule :C39H45Cl2F3N8O3Couleur et forme :SolidMasse moléculaire :801.728HAT-SIL-TG-1&AT
HAT-SIL-TG-1&AT: a hypoxia-activated JAK inhibitor that curbs HEL cell growth & STAT3/5 phosphorylation in tumors.Formule :C60H69N17O11SCouleur et forme :SolidMasse moléculaire :1236.36FLT3/VEGFR2-IN-1
FLT3/VEGFR2-IN-1 (Compound 26) is a potent inhibitor of FLT3, VEGFR2, and HDAC, exhibiting IC50 values of 14.5 nM, 3.9 nM, and 30.8 nM against FLT3, VEGFR2, and HDAC1, respectively. It effectively inhibits the phosphorylation of STAT3 and ERK1/2, as well as the proliferation of leukemia cells. FLT3/VEGFR2-IN-1 demonstrates antitumor activity and is applicable in research on acute myeloid leukemia.Formule :C29H35N7O5Couleur et forme :SolidMasse moléculaire :561.63hCA/VEGFR-2-IN-1
hCA/VEGFR-2-IN-1 (compound 13a) is a potent dual inhibitor targeting both Carbonic Anhydrase (CA) IX/XII and Vascular Endothelial Growth Factor Receptor 2 (Formule :C21H17FN6O3SDegré de pureté :98%Couleur et forme :SolidMasse moléculaire :452.46FAK PROTAC B5
CAS :FAK PROTAC B5: a degrader with 14.9 nM IC50, strong degradation, anti-growth, good plasma stability, and fair permeability.Formule :C41H43ClN10O7Couleur et forme :SolidMasse moléculaire :823.3EGFR-IN-131
EGFR-IN-131 (compound 3a) is an efficacious EGFR inhibitor capable of crossing the blood-brain barrier, with an IC50 value of 272.9 nM. This compound exhibits anti-proliferative activity, induces cellular apoptosis (apoptosis), and causes cell cycle arrest in the G0/G1 phase. Additionally, EGFR-IN-131 reduces the protein expression of p-EGFR.Formule :C26H23FN4O2SCouleur et forme :SolidMasse moléculaire :474.55LC-SF-14
LC-SF-14 is a selective dual inhibitor of SHP2 and FGFR, with IC50 values of 71.6 nM and 8.9 nM, respectively. It blocks FGFR2-FRS2α-SHP2-MAPK signaling and ERK phosphorylation, and also inhibits the proliferation of KATOIII cancer cells (IC50: 9.2 nM). Furthermore, LC-SF-14 exhibits antitumor activity in SNU-16 xenograft mouse models, making it suitable for research on FGFR2-driven gastric cancer.Formule :C44H50Cl3N13O5SCouleur et forme :SolidMasse moléculaire :977.28442PROTAC FLT3/CDK9 degrader-1
Potent PROTAC degrader for FLT3/CDK9, induces apoptosis, and shows promise for FLT3-ITD mutated AML research.Formule :C48H62N12O7Couleur et forme :SolidMasse moléculaire :919.08BIIB091
CAS :BIIB091 is a highly selective, reversible BTK inhibitor for treating autoimmune diseases.Formule :C28H34N10O2Couleur et forme :SolidMasse moléculaire :542.648FLT3-IN-23
FLT3-IN-23 (compound 15), a potent inhibitor of FMS-like tyrosine kinase 3 (FLT3), exhibits an IC 50 value of 7.42 nM and demonstrates antiproliferative effectsCouleur et forme :Odour SolidFGFR1 inhibitor-2
CAS :FGFR1 inhibitor-2, potent at 4.55 μM IC50 in MDA-MB-231, targets triple-negative breast cancer.Formule :C25H22F5N3O3Couleur et forme :SolidMasse moléculaire :507.461Sotiburafusp alfa
CAS :Sotiburafusp alfa is a humanized bispecific fusion protein comprising a VEGFR-1 extracellular domain fragment (129-228, 1-100 in the current sequence) connectedDegré de pureté :98%Couleur et forme :SolidBefotertinib
CAS :Befotertinib (D-0316) is an inhibitor of EGFR tyrosine kinase and can be used for studies about EGFR T790M-positive non-small cell lung cancer.Formule :C29H32F3N7O2Degré de pureté :99.83%Couleur et forme :SolidMasse moléculaire :567.61Ref: TM-T39275
1mg84,00€5mg177,00€10mg281,00€25mg497,00€50mg708,00€100mg973,00€1mL*10mM (DMSO)222,00€Ibrutinib-biotin
CAS :Ibrutinib-biotin probe links Ibrutinib to biotin, with IC50 0.755-1.02 nM for BTK (patent WO2014059368A1).Formule :C56H80N12O9SDegré de pureté :98%Couleur et forme :SolidMasse moléculaire :1097.39VEGFR/PARP-IN-1
VEGFR/PARP-IN-1 (Compound 14b) is a dual inhibitor of VEGFR and PARP with IC50 values of 191 nM and 60.9 nM, respectively.Formule :C29H27N9ODegré de pureté :98%Couleur et forme :SolidMasse moléculaire :517.58VEGFR-2-IN-61
VEGFR-2-IN-61 (Compound 7b) is an inhibitor of VEGFR-2 with an IC50 of 2.83 µM. It effectively inhibits the proliferation of various cancer cells, including MCF-7 cells, with an IC50 of 2.12 µM. Additionally, VEGFR-2-IN-61 suppresses cell migration and induces oxidative stress and apoptosis in MCF-7 cells.Formule :C27H25N5OCouleur et forme :SolidMasse moléculaire :435.52Adenosine receptor modulator 1
Adenosine receptor modulator 1 acts as an inducer of collagen VII (C7). It enhances the expression of COL7A1 mRNA in donor-derived keratinocytes and, in synergy with Gentamicin, increases the overall levels of C7.Formule :C25H28N6O3Couleur et forme :SolidMasse moléculaire :460.53AKN-028
CAS :AKN-028 is an orally active and potent FLT3 tyrosine kinase inhibitor ( IC 50 = 6 nM). AKN-028 causes dose-dependent inhibition of FLT3 autophosphorylation.
Formule :C17H14N6Degré de pureté :99.88%Couleur et forme :SolidMasse moléculaire :302.33TLT8
TLT8 is a ByeTAC protein degrader that targets BTK. It induces BTK degradation by non-covalently binding to Rpn-13 and BTK. TLT8 is applicable in research on chronic lymphocytic leukemia.Couleur et forme :Odour SolidCS-VIP 8 TFA
CS-VIP 8 TFA is a selective allosteric inhibitor of the WDR5 protein (Ki= 0.008 μM). It induces a conformational change in the MLL1 complex, leading to the dissociation of MLL1 from the complex, thereby inhibiting the MLL1 histone methyltransferase activity and modulating HOX gene expression. CS-VIP 8 TFA shows potential for research in hematological disorders such as leukemia.Formule :C45H53F7N12O9Couleur et forme :SolidMasse moléculaire :1038.39467EGFR-TK-IN-5
EGFR-TK-IN-5 (Compound NCE 2) is a thiazolyl pyrazoline derivative with significant inhibitory activity and stability against EGFR. It is applicable in tumor research.Formule :C26H20ClFN4OSCouleur et forme :SolidMasse moléculaire :490.98LCB 03-0110
CAS :LCB 03-0110 (3-(2-(3-(Morpholinomethyl)phenyl)thieno[3,2-b]pyridin-7-ylamino)phenol) is a potent inhibitor of discoidin domain receptor family tyrosine kinasesFormule :C24H23N3O2SDegré de pureté :99.12%Couleur et forme :SolidMasse moléculaire :417.52Ref: TM-T9659
1mg115,00€5mg249,00€10mg368,00€25mg562,00€50mg787,00€100mg1.054,00€1mL*10mM (DMSO)280,00€SNIPER(ABL)-020
SNIPER(ABL)-020, a Dasatinib-Bestatin conjugate via linker, inhibits ABL and targets IAP, reducing BCR-ABL protein.Formule :C44H59ClN10O8SDegré de pureté :98%Couleur et forme :SolidMasse moléculaire :923.52EGFR-IN-83
EGFR-IN-83 (Compound 9), an EGFR inhibitor with an IC50 of 2.53 nM, exhibits antiproliferative effects on MCF-7 and MDA-MB-231 cell lines, with respective IC50Formule :C22H17F3N4ODegré de pureté :98%Couleur et forme :SolidMasse moléculaire :410.39DSPE-PEG5000-A7R
DSPE-PEG5000-A7R is a PEG compound composed of DSPE and the tumor vascular targeting peptide (A7R). The peptide A7R exhibits high affinity and specificity for VEGFR-2, which is overexpressed in various tumors.Couleur et forme :Odour SolidFAK-IN-9
CAS :FAK-IN-9 (8f) is a potent oral FAK inhibitor, IC50 of 27.44 nM; induces TNBC cell apoptosis.Formule :C36H38ClN7O8SCouleur et forme :SolidMasse moléculaire :764.25GC1118
GC1118 (GC-1118A) is a fully human anti-EGFR monoclonal antibody with a KD value of 0.16 nM against EGFR. It potently inhibits signal transduction triggered by both high-affinity and low-affinity EGFR ligands. GC1118 exhibits strong antiproliferative activity in both KRAS wild-type and KRAS mutant cells. It can penetrate the blood-brain barrier (BBB) and blood-tumor barrier (BTB) to reach tumor sites and demonstrates excellent antitumor effects in various mouse xenograft models. GC1118 is applicable for cancer studies, including colorectal cancer.Couleur et forme :Odour LiquidRR-src
CAS :Tyrosine kinase substrate peptideFormule :C64H106N22O21Degré de pureté :98%Couleur et forme :Lyophilized PowderMasse moléculaire :1519.663-Methylthienyl-carbonyl-JNJ-7706621
CAS :Potent CDK inhibitor 3-Methylthienyl-carbonyl-JNJ-7706621, IC50: CDK1=6.4nM, CDK2=2nM, GSK-3=0.041μM; moderate on CDK4/VEGF-R2/FGF-R2.Formule :C14H14N6O3S2Couleur et forme :SolidMasse moléculaire :378.43PROTAC EGFR degrader 5
CAS :PROTAC EGFR degrader 5 effectively breaks down EGFR Del19 in HCC827 cells at 34.8 nM, inducing apoptosis and G1 arrest.Formule :C57H72FN13O5SCouleur et forme :SolidMasse moléculaire :1070.33
